[
  {
    "ts": null,
    "headline": "Boston Scientific Corporation (BSX) Presents at Citi Annual Global Healthcare Conference 2025 Prepared Remarks Transcript",
    "summary": "Boston Scientific Corporation (BSX) Citi Annual Global Healthcare Conference 2025 December 2, 2025 9:00 AM ESTCompany ParticipantsLauren Tengler - Director...",
    "url": "https://finnhub.io/api/news?id=65f66011750005491ed9ab2f6428e86151206b8f28b4af805c7137107789ae28",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764692605,
      "headline": "Boston Scientific Corporation (BSX) Presents at Citi Annual Global Healthcare Conference 2025 Prepared Remarks Transcript",
      "id": 137664808,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Boston Scientific Corporation (BSX) Citi Annual Global Healthcare Conference 2025 December 2, 2025 9:00 AM ESTCompany ParticipantsLauren Tengler - Director...",
      "url": "https://finnhub.io/api/news?id=65f66011750005491ed9ab2f6428e86151206b8f28b4af805c7137107789ae28"
    }
  },
  {
    "ts": null,
    "headline": "Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.",
    "summary": "Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion’s commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a heal",
    "url": "https://finnhub.io/api/news?id=049d54909fb0157ad0cd341c04c818e4bdc15c948af57759446ef22b7e6c87af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764680400,
      "headline": "Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.",
      "id": 137662305,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion’s commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a heal",
      "url": "https://finnhub.io/api/news?id=049d54909fb0157ad0cd341c04c818e4bdc15c948af57759446ef22b7e6c87af"
    }
  },
  {
    "ts": null,
    "headline": "M&A Strategy Strengthens Boston Scientific's Growth Prospects",
    "summary": "BSX accelerates growth as a wave of acquisitions boosts core portfolios and fuels expansion into high-growth adjacent markets.",
    "url": "https://finnhub.io/api/news?id=4280dbcdd976ebb02fe952678fab70c24c561f67bc71468b50cb305015dc59a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764680160,
      "headline": "M&A Strategy Strengthens Boston Scientific's Growth Prospects",
      "id": 137662306,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "BSX accelerates growth as a wave of acquisitions boosts core portfolios and fuels expansion into high-growth adjacent markets.",
      "url": "https://finnhub.io/api/news?id=4280dbcdd976ebb02fe952678fab70c24c561f67bc71468b50cb305015dc59a0"
    }
  },
  {
    "ts": null,
    "headline": "Should You Continue to Hold LH Stock in Your Portfolio?",
    "summary": "Labcorp expands in specialty testing and ramps up acquisitions, but macro pressures and currency headwinds complicate its growth outlook.",
    "url": "https://finnhub.io/api/news?id=2f3578a81cb91e694da198e389351cbb665eb5a3be8535b2908a3e8a7af4b581",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764679980,
      "headline": "Should You Continue to Hold LH Stock in Your Portfolio?",
      "id": 137662307,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Labcorp expands in specialty testing and ramps up acquisitions, but macro pressures and currency headwinds complicate its growth outlook.",
      "url": "https://finnhub.io/api/news?id=2f3578a81cb91e694da198e389351cbb665eb5a3be8535b2908a3e8a7af4b581"
    }
  }
]